Current Clinical Trials

Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: AbbVie
Indentifier #: NCT02032277
Title: M14-011, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of the Addition of a PARP Inhibitor Plus Carboplatin Versus the Addition of Carboplatin in Combination with Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SWOG
Indentifier #: NCT01272037
Title: S1007, A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT00828009
Title: E6508, A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Amgen
Title: Amgen 20130110; Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients Neulasta
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SWOG
Indentifier #: NCT01674140
Title: S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer